Physician profile
Amit Kumar Trehan
NPI 1952308108
$7,615.22
in general payments reported to CMS, 2019-2025
28 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,015 · 2020: $163 · 2021: $604 · 2022: $682 · 2023: $1,390 · 2024: $1,460 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,150.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,297.11 | 2019-2025 | Mavyret, Rinvoq, Skyrizi |
| Allergan, INC. | $1,666.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $784.07 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $342.88 | 2019-2025 | |
| Gilead Sciences, INC. | $309.73 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.11 | 2021-2024 | Trulance |
| Intercept Pharmaceuticals, INC. | $179.85 | 2020-2025 | Ocaliva |
| Janssen Biotech, INC. | $174.15 | 2022-2025 | Tremfya, Stelara, Simponi |
| Aimmune Therapeutics, INC. | $170.86 | 2024-2025 | Vowst, Zenpep |
| Celgene Corporation | $161.10 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $160.24 | 2020-2023 | |
| Ferring Pharmaceuticals INC. | $139.23 | 2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $118.43 | 2024-2025 | Voquezna |
| Amgen INC. | $116.64 | 2025 | Uplizna |
| Ardelyx, INC. | $112.78 | 2023-2025 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.66 | 2023-2024 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $106.39 | 2024-2025 | Iqirvo, Bylvay |
| Daiichi Sankyo INC. | $100.00 | 2019-2024 | Injectafer |
| Genzyme Corporation | $59.40 | 2023-2024 | |
| Astellas Pharma US INC | $54.48 | 2020 | |
| Qol Medical, LLC | $50.20 | 2024-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $39.13 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $36.70 | 2024-2025 | Dupixent |
| Olympus America INC. | $27.57 | 2019 | |
| Shire North American Group INC | $22.08 | 2019 | |
| Merck Sharp & Dohme LLC | $19.38 | 2023 | Dificid |
| Lilly USA, LLC | $15.18 | 2025 | Omvoh |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$104,018.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Trehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.